Shuailiang Lin, PhD

Associate Director, Translational Sciences

Shuailiang Lin is the Associate Director of Translational Sciences at Kriya Therapeutics. Previously, Dr. Lin was the Director of Genome Editing at Ligandal Inc, where he built and led a team focused on gene editing, gene delivery, and TCR engineering of T cells. Dr. Lin was also part of the early team involved in the development of the CRISPR/Cas9 genome engineering system in Feng Zhang’s lab at The Broad Institute. He has more than 10 years of experience in genome engineering and gene delivery.

Dr. Lin received his PhD from Tsinghua University and completed his postdoctoral fellowship at the University of California, San Francisco. He received his undergraduate degree in Biological Sciences from the China Agricultural University.